Vani Janakiraman, Elluru Sriramulu, Negi Vir-Singh, Lacroix-Desmazes Sébastien, Kazatchkine Michel D, Bayry Jagadeesh, Kaveri Srini V
Centre de Recherche des Cordeliers, Equipe 16 - Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie - Paris 6, UMR S 872, Paris, F-75006, France.
Autoimmun Rev. 2008 Jun;7(6):440-4. doi: 10.1016/j.autrev.2008.04.011. Epub 2008 Apr 28.
Intravenous immunoglobulin (IVIg) has increasingly been used for the treatment of autoimmune and systemic inflammatory diseases in addition to supportive therapy of immunodeficient patients. Although a considerable progress has been made in understanding the mechanisms by which IVIg exerts immunomodulatory functions in these diseases, they remain not fully elucidated. The mode of action of IVIg is complex, involving interference with activation of complement and the cytokine network, modulation of: idiotype network, expression of Fc receptors, and activation, differentiation and effector functions of T and B cells and of antigen-presenting cells such as dendritic cells. The therapeutic effects of IVIg most likely reflect the functions of natural antibodies in maintaining immune homeostasis in healthy individuals.
静脉注射免疫球蛋白（IVIg）除了用于免疫缺陷患者的支持治疗外，越来越多地被用于治疗自身免疫性疾病和全身性炎症性疾病。尽管在理解IVIg在这些疾病中发挥免疫调节功能的机制方面已经取得了相当大的进展，但这些机制仍未完全阐明。IVIg的作用方式很复杂，涉及干扰补体和细胞因子网络的激活、调节独特型网络、Fc受体的表达以及T细胞、B细胞和抗原呈递细胞（如树突状细胞）的激活、分化和效应功能。IVIg的治疗效果很可能反映了天然抗体在维持健康个体免疫稳态中的作用。
